Clinical Certificate


This module was originally scheduled for 30 April – 1 May
Date: Thursday 5th November 2020 – Friday 6th November 2020
Venue: The Radisson Park Inn Hotel, 4 Cheetham Hill Rd, Manchester, M4 4EW
Accommodation: The Radisson Park Inn Hotel, 4 Cheetham Hill Road, Manchester, M4 4EW
(accommodation is bookable separately when you complete the online booking form)
Organised by: Professor Jo Neill and Dr Richard Drake


Thursday 5 November
09:45–10:15 Arrival, Registration and Coffee
10:15–10:20 Introduction
Professor Jo Neill (Manchester)
10:20–10:55 Causes of schizophrenia: Introduction to current thinking
Professor Shôn Lewis (Manchester)
10:55–11:45 Early intervention in psychosis and inflammation
Professor Rachel Upthegrove (Birmingham)
11:45–11:55 Q&A session
11:55–12:30 New trial data and clinical guidelines
Professor Shôn Lewis (Manchester)
12:30–12:40 Q&A session
12:45–13:30 Lunch in the Restaurant
13:30–14:20 Recent developments in the psychopharmacological understanding of schizophrenia
Professor Bill Deakin (Manchester)
14:20–14:30 Q&A session
14:30–15:20 Genetics of schizophrenia, pharmacogenomics and treatment response
Professor Liz Tunbridge (Oxford)
15:20–15:30 Q&A session
15:30–16:00 Refreshments and delegates split into 3 groups
16:00–17:30 Group Work – Split into three groups
Group A: Treatment Problems
Dr Richard Drake (Manchester)
Group B: Treatment Problems
Professor Rachel Upthegrove (Birmingham)
Group C: Treatment Problems
Professor David Owens (Edinburgh)
17:30 End of Thursday Sessions
Friday 6 November
08:30–08:45 Arrival and Coffee
08:45–09:45 Antipsychotics and relapse prevention in schizophrenia
09:45–10:00 Q&A session
10:00–10:30 Refreshments
10:30–11:15 Pharmacology of antipsychotic medication and adherence
Dr Richard Drake (Manchester)
11:15–11:30 Q&A session
11:30–12:30 Pharmacological strategies for treatment-resistant schizophrenia
12:30–12:45 Q&A session
12:45–13:35 Lunch in the Restaurant
13:35–14:45 EPS Update
Professor David Owens (Edinburgh)
14:45–15:15 Q&A session
15:15 Meeting ends. Return of evaluation forms

Last edited 4th June 2020

Learning Objectives

At the end of this module, the attendees will:

  • Be aware of current theories of the causes and neurochemistry of schizophrenia
  • Know the pharmacology of conventional and atypical drugs
  • Be aware of the clinical assessment of therapeutic and adverse effects
  • Have an opinion about relative benefits of conventional and atypical drugs
  • Be updated on guidelines and the social context of drug prescribing in schizophrenia
  • Have had an opportunity to discuss difficult management problems with colleagues and experts

This module is eligible for 11 CPD hours which are subject to peer group review.

For further details contact Susan Chandler, BAP Executive Officer:

Feedback from 2019 Module

"Excellent course. Really well organised and a great atmosphere for learning. Lovely food and I learnt so much. Very good value for money – BAP runs the best courses around!"

"Excellently organised meeting, clinically applicable and kudos to presenters and organisers"

"Thank you for an excellent course, I will recommend to colleagues"

"Really enjoyable and insightful, I have learnt a lot and it was highly relevant/practical to my clinical work"

Print DOIs